• Vaccine Name: T. pallidum GlpQ Protein Vaccine
• Target Pathogen: Treponema pallidum
• Target Disease: Syphilis
• Vaccine Ontology ID: VO_0004024
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant GlpQ
• GlpQ gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant: Ribi vaccine adjuvant
  • Adjuvant name: Ribi vaccine adjuvant
  • VO adjuvant ID: VO_0001238
• Immunization Route: IM, SC, IP, and ID

Rabbit Response

• Host Strain: New Zealand White
• Vaccination Protocol: Rabbits were immunized three times (IM, SC, IP, and ID) at 3-week intervals with the Ribi MPL + TDM + CWS adjuvant and 100 μg of purified inclusion bodies from E. coli expressing either the pET-3a vector alone or the Gpd-pET-3a construct (Cameron et al., 1998).
• Challenge Protocol: Two weeks after administration of the final immunization, rabbits were challenged ID at each of six sites on their shaved backs with 103 T. pallidum per site (Cameron et al., 1998).
• Efficacy: Immunization with the recombinant GlpQ significantly protected rabbits from subsequent T. pallidum challenge, altering lesion development at the sites of challenge. All eight control rabbits developed typical red, raised, and highly indurated lesions at each of the six challenge sites that in some cases progressed to ulceration. All four of the Gpd-immunized rabbits developed atypical pale, flat, slightly indurated, and nonulcerative reactions at each of the six challenge sites. In all cases, induration in the Gpd-immunized animals resolved before lesions appeared in the control animals and resembled delayed-type hypersensitivity responses more than typical syphilis chancres (Cameron et al., 1998).